146 related articles for article (PubMed ID: 36084297)
21. Combined intraocular and systemic rituximab for ocular lymphoproliferative disorder with extranodal marginal zone lymphoma-type morphology after heart transplant.
Bata BM; Pulido JS; Patel SV; Khan SP; Salomao D; Boyce TG; Bothun ED
J AAPOS; 2018 Apr; 22(2):159-161. PubMed ID: 29408337
[TBL] [Abstract][Full Text] [Related]
22. Multifocal extranodal mucosa-associated lymphoid tissue lymphoma affecting the larynx.
Arndt S; Veelken H; Schmitt-Gräff A; Aschendorff A; Maier W; Richter B
Ann Otol Rhinol Laryngol; 2007 Apr; 116(4):257-61. PubMed ID: 17491523
[TBL] [Abstract][Full Text] [Related]
23. [Extranodal marginal zone lymphoma of the ocular adnexa].
Møller A; Specht L; Toft PB; Sjø LD
Ugeskr Laeger; 2008 Nov; 170(45):3660-3. PubMed ID: 18986616
[TBL] [Abstract][Full Text] [Related]
24. Intralesional Rituximab for the Treatment of Recurrent Ocular Adnexal Lymphoma.
Demirci H; Kauh CY; Rajaii F; Elner VM
Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S70-S71. PubMed ID: 26950471
[TBL] [Abstract][Full Text] [Related]
25. Intralesional interferon-α for the treatment of bilateral conjunctival mucosa-associated lymphoid tissue lymphoma.
Holds J; Buchanan A; Hanson R
Pediatr Blood Cancer; 2012 Jul; 59(1):176-8. PubMed ID: 21793177
[TBL] [Abstract][Full Text] [Related]
26. Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience.
Tuncer S; Tanyıldız B; Basaran M; Buyukbabani N; Dogan O
Curr Eye Res; 2015; 40(8):780-5. PubMed ID: 25247376
[TBL] [Abstract][Full Text] [Related]
27. Results of Upfront Therapy for Marginal Zone Lymphoma.
Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
[TBL] [Abstract][Full Text] [Related]
28. Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome.
Eberle FC; Holstein J; Scheu A; Fend F; Yazdi AS
J Dtsch Dermatol Ges; 2017 Mar; 15(3):319-323. PubMed ID: 28177583
[TBL] [Abstract][Full Text] [Related]
29. Intralesional rituximab for primary iris lymphoma.
Demirci H; Grant JS; Elner VM
JAMA Ophthalmol; 2015 Jan; 133(1):104-5. PubMed ID: 25211092
[No Abstract] [Full Text] [Related]
30. Interferon alpha in the therapy of conjunctival lymphoma in an HIV+ patient.
Cellini M; Possati GL; Puddu P; Caramazza R
Eur J Ophthalmol; 1996; 6(4):475-7. PubMed ID: 8997596
[TBL] [Abstract][Full Text] [Related]
31. Conjunctival malt lymphoma successfully treated with single agent rituximab therapy.
Salepci T; Seker M; Kurnaz E; Guler DO; Bilici A; Dane F; Aliustaoglu M; Atesoglu EB; Gumus M; Yaylaci M
Leuk Res; 2009 Mar; 33(3):e10-3. PubMed ID: 18653234
[No Abstract] [Full Text] [Related]
32. [Extranodal non-Hodgkin's lymphoma of MALT-type stage I. A case report].
Kuhnt T; Wollschläger B; Bloching M; Krause U; Dunst J
Strahlenther Onkol; 2003 Jun; 179(6):396-400. PubMed ID: 12789466
[TBL] [Abstract][Full Text] [Related]
33. Rituximab-induced remission of a gastric MALT lymphoma.
Datta YH; Kampalath B; Binion DG
Leuk Lymphoma; 2004 Jun; 45(6):1297-9. PubMed ID: 15360017
[TBL] [Abstract][Full Text] [Related]
34. Extranodal marginal zone B-cell lymphoma most probably of MALT type appearing in CNS as parasagittal extracerebral tumor.
Marinković M; Slavik E; Janković S; Cemerikic V; Radulović D
J Neurosurg Sci; 2006 Mar; 50(1):9-12. PubMed ID: 16557194
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of local radiotherapy in primary extranodal marginal zone B-cell lymphoma of MALT or MALT lymphoma of conjunctiva: study of four cases.
Xicoy B; Ribera JM; Arellano A; Mate JL; Millá F; Feliu E
Leuk Lymphoma; 2002 Oct; 43(10):1975-7. PubMed ID: 12481895
[TBL] [Abstract][Full Text] [Related]
36. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
[TBL] [Abstract][Full Text] [Related]
37. Improvement of Severe Colon Stricture after Rituximab Therapy for Concomitant Mucosa-associated Lymphoid Tissue Lymphoma in a Patient with Ulcerative Colitis.
Park HJ; Moon W; Park SJ; Park MI; Kim SE; Kim JH; Jung K; Seo KI; Lee EM; Jung M
Korean J Gastroenterol; 2023 Nov; 82(5):254-260. PubMed ID: 37997222
[TBL] [Abstract][Full Text] [Related]
38. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
Esmaeli B; McLaughlin P; Pro B; Samaniego F; Gayed I; Hagemeister F; Romaguera J; Cabanillas F; Neelapu SS; Banay R; Fayad L; Wayne Saville M; Kwak LW
Ann Oncol; 2009 Apr; 20(4):709-14. PubMed ID: 19150940
[TBL] [Abstract][Full Text] [Related]
39. Conjunctival extranodal marginal zone B-cell lymphoma with crystal-storing histiocytosis.
Mittal R; Damato B; Coupland SE
Acta Ophthalmol; 2015 Nov; 93(7):e602-3. PubMed ID: 25988528
[No Abstract] [Full Text] [Related]
40. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
